Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECOSPOR: SER-109 for Recurrent CDI
NCT02437487Phase 2Completed
- Sponsor
- Seres Therapeutics
- Start
- May 2015
- Primary completion
- Jul 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of fecal microbiota, live-brpk in Clostridioides difficile infection (CDI), sponsored by Seres Therapeutics. Started May 2015; status: completed.
02
Drugs
fecal microbiota, live-brpk
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02437487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437487.